Leukoreduction of blood components

Current Opinion in Hematology

Volumn 9, Issue 6, 2002, Pages 521-526

  Dzik, Walter H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; BLOOD COMPONENT THERAPY; BLOOD FILTER; BLOOD FILTRATION; BLOOD TRANSFUSION REACTION; CANCER RECURRENCE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEART PERFUSION; HLA SYSTEM; HUMAN; LEUKOCYTE COUNT; LEUKOREDUCTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; VIRUS ACTIVATION; VIRUS TRANSMISSION; BLOOD BANK; CELL SEPARATION; DISEASE TRANSMISSION; FILTRATION; INSTRUMENTATION; LEUKOCYTE; METHODOLOGY; SECOND CANCER; STANDARD; VIRUS INFECTION;

BLOOD BANKS; BLOOD COMPONENT TRANSFUSION; CELL SEPARATION; FILTRATION; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; NEOPLASMS, SECOND PRIMARY; VIRUS DISEASES;

EID: 0036839388     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200211000-00010     Document Type: Review

References (26)

1. Collier AC, Kalish LA, Busch MP, et al.: Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001, 285:1592-1601.
2. Vamvakas EC, Blajchman MA.: Universal WBC reduction: the case for and against. Transfusion 2001, 41:691-712.
3. van de Watering LMG, Brand A, Houbiers JGA, et al., for the Cancer Recurrence and Blood Transfusion study group: Perioperative blood transfusions, with or without allogeneic leukocytes, relate to survival, not to cancer recurrence. Br J Surg 2001, 88:267-272.
4. Titlestad IL, Ebbesen LS, Ainsworth AP, et al.: Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications: results of a double-blinded, randomized study. Int J Colorectal Dis 2001, 16:147-153.
5. Dzik S, Anderson JK, O'Neill M, et al.: A prospective randomized clinical trial of universal leukoreduction [abstract]. Transfusion 2001, 41(Suppl):1S.
6. Baron JF, Gourdin M, Bertrand M, et al.: The effect of universal leukodepletion of packed red blood cells on postoperative infections in high-risk patients undergoing abdominal aortic surgery. Anesth Analg 2002, 94:529-537.
7. Matheis G, Scholz M, Simon A, et al.: Leukocyte filtration in cardiac surgery: a review. Perfusion 2001, 15:361-370.
8. Chen YF, Tsai WC, Lin CC, et al.: Leukocyte depletion attenuates expression of neutrophil adhesion molecules during cardiopulmonary bypass in human beings. J Thorac Cardiovasc Surg 2002, 123:218-224.
9. Sahlman A, Ahonen J, Salo JA, et al.: No impact of a leukocyte depleting arterial line filter on patient recovery after cardiopulmonary bypass. Acta Anesthesiol Scand 2001, 45:558-563.
10. Ratko TA, Cummings JP, Oberman HA, et al.: Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion 2001, 41:1310-1319.
11. Laupacis A, Brown J, Costello B, et al.: Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion 2001, 41:560-569.
12. Sweeney JD: Universal leukoreduction of cellular blood components in 2001? Yes. Am J Clin Pathol 2001, 115:666-673.
13. Goodnough LT: Universal leukoreduction of cellular blood components in 2001? No. Am J Clin Pathol 2001, 115:674-677.
14. Engelfriet CP, Reesink HW, Pietersz RN, et al.: Universal leukocyte-depletion of blood components: cell concentrates and plasma. Vox Sang 2001, 81:56-77.
15. CBER: Draft guidance for industry: pre-storage leukocyte reduction of whole blood components intended for transfusion. January 2001. Available at: http://www.fda.gov/cber/gdlns/preleuk.htm. Accessed May 21, 2002.
16. Pennington J, Garner SF, Sutherland J, et al.: Residual subset population analysis in WBC-reduced blood components using real-time PCR quantitation of specific mRNA. Transfusion 2001, 41:1591-1600.
17. Lee TH, Wen L, Chrebtow V, et al.: Quantitation of residual WBCs in filtered blood components by high-throughput, real-time kinetic PCR. Transfusion 2002, 42:87-93.
18. van der Meer PF, Gratama JW, van Delden CJ, et al.: Comparison of five platforms for enumeration of residual leukocytes in leucoreduced blood components. Br J Haematol 2001, 115:953-962.
19. Dzik WH, Moroff G, Dumont LJ: A multicenter study evaluating three methods for counting residual leukocytes in leukoreduced blood components: Nageotte hemacytometry, flow cytometry, and microfluorometry. Transfusion 2000, 40:513-520.
20. Yomtovian R, Gernsheimer T, Assmann SF, et al., for the Viral Activation Transfusion Study Group: WBC reduction in RBC concentrates by prestorage filtration: multicenter experience. Transfusion 2001, 41:1030-1036.
21. Chabanel A, Andreu G, Carrat F, et al.: Quality control of leucoreduced cellular blood components in France. Vox Sang 2002, 82:67-71.
22. Gorlin JB, Gudino MD: A sticky situation: WBC reduction of RBCs from donors with sickle trait. Transfusion 2001, 41:1192.
23. Muller-Steinhardt M, Hennig H, Kirchner H, et al.: Prestorage WBC filtration of RBC units with soft-shell filters: filtration performance and impact on RBCs during storage for 42 days. Transfusion 2002, 42:153-158.
24. Brecher ME, Triulzi DJ, Assmann SF, for the Viral Activation Transfusion Study: Number of RBC units and rate of transfusion to anemic HIV-positive patients assigned to receive WBC-reduced or non-WBC-reduced RBCs: the Viral Activation Transfusion Study experience. Transfusion 2001, 41:794-798.
25. Cyr M, Eastlund T, Blais C, et al.: Bradykinin metabolism and hypotensive reactions. Transfusion 2001, 41:136-150.
26. Lavee J, Paz Y: Hypotensive reactions associated with transfusion of bedside leukocyte-reduction filtered blood products in heart transplanted patients. J Heart Lung Transplant 2001, 20:759-761.